Global Gene Panel Market is segmented By Product & Service (Test Kits, Testing Services), By Technique (Hybridization-based Approach, Amplicon-based Approach), By Design (Predesigned Gene Panel, Customized Gene Panel), By Application (Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics, Other Applications), By End-user (Hospital and Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024 - 2031
Gene Panel Market Overview
[180 pages] Report on Global Gene Panel by DataM Intelligence estimates the market to grow at a CAGR of 19.6% during the forecast period 2024 - 2031.
Gene Panel usage in analysing multiple genes is on the rise. Demand from Biotechnology Companies, Diagnostic Laboratories, and Research Institutes in North America is booming. The competitive rivalry intensifies with Thermo Fisher Scientific, Eurofins Scientific, Genewiz Inc and others operating in the market.
A gene panel is a test that helps analyze multiple genes at the same time for cancer-associated mutations. BRCA1 and BRCA2 are two genes responsible for the production of proteins that help in suppressing tumors. These proteins help in repairing damaged DNA and prevent the growth of tumor cells.
Gene Panel Market Scope and Summary
|
Metrics |
Details |
|
Market CAGR |
19.6% |
|
Segments Covered |
By Product & Service, By Technique, By Design, By Application, By End-user and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Source: DataM Intelligence Analysis (2020)
Gene Panel Market Trends and Dynamics
The gene panel market growth is driven by the rising prevalence of chronic diseases and increasing technological advancement in diagnostics services and methods, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer.
The rising prevalence of chronic disease is expected to drive growth in the forecast period.
The gene panels are used in diagnostics and treatments like Cancer Risk Assessment, Syndrome-Specific Diagnostics, Disease Penetration, and many other applications. Based on the data published by the World Health organization, in 2020, the chronic disease contribution is expected to rise to 73% of all deaths and 60% of the global burden of disease. Moreover, 79% attributed to these diseases occur in developing countries. Four of the most prominent chronic diseases are cardiovascular diseases (CVD), cancer, chronic obstructive pulmonary disease, and diabetes. This will ultimately upsurge the demand for gene panels over the forecasted period.
The rising adoption of gene panel owing to the benefits they offer is expected to drive the growth in the forecast period.
A multi-gene panel test provides better diagnostic yield than a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer. This single reliable test provides more information for women suspected to have hereditary cancer predisposition, particularly for breast and ovarian cancers. Besides this, in a retrospective comparison of multiple genetic tests, there was no difference between the multi-gene panel test and the limited BRCA1/2 test in the detection of potentially harmful BRCA mutations.
The rising security concerns for genetic data are likely to hamper market growth.
Genetic data is the most personal data any individual may have. Also, it is an ultimate unique identifier of all living things. Besides this, the information breaches regarding the same can't be retrieved since it is not like other websites and banking passwords that can be changed over time. The gene data for each living thing across the world is unique and cannot be changed throughout a lifetime. This might restrict the usage of gene testing across the healthcare and research & development sector. Since the data is so valuable, hackers may have an incentive to target genetic databases to acquire data that can be used in financial or identity fraud.
COVID-19 Impact Analysis on Gene Panel Market
The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 pandemic has left a significant impact on the growth of genetic testing services. Most of the genetic testing services have adopted virtualization and a home testing kit/home sample collection to combat the transmission of the COVID-19. However, there was a hindrance in accessing genetic testing blood draws, leading to a decrease in the demand for genetic testing. Thus, negatively impacting the demand for gene panel worldwide.
Gene Panel Market Segmentation Analysis
The test kits segment is expected to hold the largest share in this market segment.
The test kits segment accounted for the largest share of the total market. The growing demand for gene panel in research and diagnostics to understand the genetic variability of chronic disorders is propelling the growth of this gene panel market segment. For instance, on October 7th, 2019, Qiagen signed a 15-year partnership with Illumina which helped to widen the availability and utilization of NGS-based in-vitro diagnostic (IVD) kits, which includes companion diagnostics for management of patient care.
The hybridization-based approach segment is expected to hold the largest share in this market segment.
Sequencing by hybridization had been extensively modified in the last decades since its discovery to enhance its accuracy. The method is quite sensitive to the hybridization errors in the spectrum; therefore, many approaches aim to create methods that improve the resistance of the hybridization phase to errors. One of the enhancements introduced additional information to the spectrum, i.e., estimated location in the target sequence for each element.
For instance, on June 18th, 2018, Thermo Fisher Scientific introduced Ion AmpliSeq Hybridization-based technology, which is a next-generation library preparation innovation.
Source: DataM Intelligence Analysis (2020)
Global Gene Panel Market Geographical Share
North America region holds the largest market share of the global gene panel market.
North America accounted for the largest market share. Consumer demand for safe and effective genetic tests is fueling the growth of the gene panel market. Nonetheless, the growing demand for personalized medicine and the growing Application of genetic testing in oncology are fueling the growth of the North American gene panel market. In addition, growth in the aging population, the subsequent increase in chronic diseases, advancements of technology in the genetic testing space, and rising cancer cases are few primary factors that are propelling the growth of the market. For instance, QIAGEN and INOVIO Expand Collaboration to Develop Next-Generation Sequencing (NGS) Companion Diagnostic for INOVIOs VGX-3100 for Advanced Cervical Dysplasia.
Gene Panel Companies and Competitive Landscape
The global gene panel market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI (China), Eurofins Scientific, Novogene Corporation (China), F. Hoffmann-La Roche AG, Integrated DNA Technologies, Genewiz, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, The Ethiopian Biotechnology Institute (EBTi) and BGI Health Ethiopia PLC signed a memorandum of understanding (MoU) in the HPV Genotyping Pilot Project and technological relations.
Gene Panel Market Key Companies to Watch
Illumina, Inc
Overview: Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a comprehensive line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. With headquarters in San Diego, California, USA and number of employees >7,800 globally with 2020 revenue around $3,236M USD.
Product Portfolio: The Company’s portfolio comprised of include innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. The company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Key developments: On April 22, 2021, Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic. With this partnership, Illumina will expand the TruSight Oncology offerings into hematologic malignancies.
Why Purchase the Report?
- Visualize the composition of the gene panel market segmentation by product & service, technique, design, application, end-user and region highlighting the key commercial assets and players.
- Identify commercial opportunities in gene panel market by analysing trends and co-development deals.
- Excel data sheet with thousands of data points of gene panel market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global gene panel market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
